Sbanken ASA :Trade subject to notification

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
38
Sbanken ASA :Trade subject to notification

Reference is made to the stock exchange notice from 27 April 2018 where the minutes from the annual general meeting of Sbanken ASA was announced. The annual general meeting granted the board of directors authorisation to acquire the company's own shares. On 12 July 2018, the board of directors resolved to use the authorisation granted by the general meeting. The purpose of the buyback is to facilitate the allocation and sale of shares to employees according to the company's share purchase program. For further details about the buy-back program, please see the minutes from the annual general meeting 27 April 2018.

On behalf of Sbanken ASA, DNB Markets has on 13 July 2018 purchased 13 590 shares for use in Sbanken's share option plan for employees.

The shares have been acquired at a price of NOK 81,99 per share. Before distribution to the employees, Sbanken has zero treasury shares.

On 7 December 2017, the board of directors of Skandiabanken ASA decided to offer employees in Skandiabanken ASA shares with a discount of NOK 1 500 - 3 000 as a part of the company's share option program.

A total of 13 590 shares were allotted today, 13 July 2018, at a gross price of 81,99 per share.

Please find enclosed a complete list of primary insiders that availed themselves of the offer, the number of acquired shares on behalf of the primary insiders and their new total shareholding after the acquisition enclosed.

Contact details, Investor Relations:

Henning Nordgulen, CFO, Skandiabanken ASA, +47 952 65 990

   This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 136

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 60

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 637

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 107

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 21

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 208

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 251

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 103

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 49

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 224

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading

Top 5 Most Recently Viewed Articles

Leadership Transition at Ignitis Renewables Sparks Future Growth

Updated Category News Views 134

Leadership Transition at Ignitis Renewables AB “Ignitis grup?” has announced a significant change in leadership with the resignation of Thierry Aelens, the Chief Executive Officer (CEO) of its subsidiary, UAB “Ignitis Renewables.” Aelens will step down effective at the end of March 2025 for personal reasons and to pursue new career opportunities nearer to his...

Continue Reading
Katalyze AI Elevates Innovation with New Chief AI Officer

Updated Category News Views 206

Advancing Pharmaceutical Manufacturing with AI Leadership Katalyze AI has recently announced a pivotal move to strengthen its capabilities in the fast-evolving field of pharmaceutical manufacturing. The company has appointed Hannes Bretschneider as Chief AI Officer, signaling its commitment to advancing Agentic AI architecture. This strategic initiative aims to enhance...

Continue Reading
Iran's Strait Closure: Defense Stocks on Edge Amid Shipping Risks

Updated Category News Views 325

Iran announced the temporary closure of the Strait of Hormuz for live-fire drills, raising eyebrows across trading desks. This isn't just a geopolitical stunt; it’s a shot across the bow at U. S. military presence in the region, occurring right as indirect nuclear talks unfold with Washington. A maneuver like this sends ripples through markets that thrive on stability,...

Continue Reading
Aphaia Pharma's Engagement in Revolutionary Obesity Forum

Updated Category News Views 117

Aphaia Pharma's Engagement in Revolutionary Obesity Forum Aphaia Pharma, a leading clinical-stage biopharmaceutical company, is making waves in the field of treatments for obesity and related metabolic disorders. The company has announced that its Chief Scientific Officer, Dr. Steffen-Sebastian Bolz, will share insights during a panel discussion at the much-anticipated...

Continue Reading
U.S. Strives to Diminish China's Dominance in Rare Earths

Updated Category News Views 216

Understanding the Importance of Rare Earth Elements In recent discussions, the significance of rare earth elements (REEs) has come to the forefront of international policy. These elements play a crucial role in various sectors, from technology to defense. Currently, China holds a dominant position in the production and refinement of these vital minerals, controlling...

Continue Reading